We have a longstanding commitment to publication of clinical trial results. Amgen is committed to the highest scientific and ethical standards for publications and is dedicated to providing scientifically accurate, fair, and well-balanced publications to the scientific community.
We consider clinical trial results for publication without regard to trial outcome or regulatory approval. We submit at least the primary analysis of all completed Amgen-sponsored phase 2 and phase 3 studies to congresses or peer reviewed journals within 18 months of trial completion.
Beyond results of individual clinical trials, we also routinely publish data from observational studies and safety registries that reflect real-world use of Amgen's products, results from integrated- and meta-analyses that permit comparative research, and biomarker studies.